ClinVar Miner

Submissions for variant NM_000404.4(GLB1):c.1051C>T (p.Arg351Ter) (rs72555372)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Genomic Research Center,Shahid Beheshti University of Medical Sciences RCV000780302 SCV000746368 pathogenic Mucopolysaccharidosis, MPS-IV-B 2020-05-03 criteria provided, single submitter clinical testing
Counsyl RCV000665526 SCV000789664 pathogenic GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis 2017-02-14 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000780302 SCV000917464 pathogenic Mucopolysaccharidosis, MPS-IV-B 2017-11-16 criteria provided, single submitter clinical testing Variant summary: The GLB1 c.1051C>T (p.Arg351X) variant results in a premature termination codon, predicted to cause a truncated or absent GLB1 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant was found in 3/246162 control chromosomes at a frequency of 0.0000122, which does not exceed the estimated maximal expected allele frequency of a pathogenic GLB1 variant (0.0020412). The c.1051C>T has been reported in at least four affected, with residual GLB1 activity in their fibroblasts being less than 2% of normal via publications. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Invitae RCV001223149 SCV001395284 pathogenic Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis 2020-09-21 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg351*) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs72555372, ExAC 0.003%). This variant has been observed to be homozygous or in combination with another GLB1 variant in individuals affected with GM1-gangliosidosis (PMID: 10841810, 15714521). ClinVar contains an entry for this variant (Variation ID: 941). Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657). For these reasons, this variant has been classified as Pathogenic.
Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit,IRCCS Fondazione Stella Maris RCV001642195 SCV001519316 pathogenic Spastic ataxia 2021-01-04 criteria provided, single submitter research
Baylor Genetics RCV001331201 SCV001523189 pathogenic Infantile GM1 gangliosidosis 2020-10-09 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
OMIM RCV000000990 SCV000021140 pathogenic GM1-gangliosidosis, type I, with cardiac involvement 2019-05-14 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.